News | July 30, 2009

New Data on Contrast Media, Kidney Damage May Impact Guidelines

July 30, 2009 - The iso-omolar contrast medium iodixanol does not yield lower rates of contrast-induced acute kidney injury (CI-AKI) than low-osmolar contrast media (LOCM), according to a meta-analysis published in the July 2009 issue of JACC: Cardiovascular Interventions.

Could these findings change current ACC/AHA guidelines, which give a class IA recommendation for iso-osmolar contrast media in patients with chronic kidney disease undergoing coronary angiography?

In the study, a team of researchers at the University of Michigan Medical School led by Hitinder Gurm, M.D., analyzed pooled data from 16 trials conducted between 1980 and 2008 that included 2,763 subjects. The studies consistently ascertained renal function data from patients randomized to either LOCM or iodixanol. The primary endpoint for the meta-analysis was the incidence of CI-AKI as defined by each individual study protocol.

Kidney injury occurred in 128 of 1,379 (9.3%) patients who received iodixanol vs. 158 of 1,375 (11.5%) patients who received LOCM. There was a trend toward a reduced relative risk of CI-AKI with iodixanol compared to LOCM as a whole, although the difference was not significant. After looking at individual types of contrast media, iodixanol did offer a significant advantage in some cases (table 1). Because only 1 study used iomeprol, an analysis was not conducted for this agent. Further, the risk of mortality and need for hemodialysis were similar between the iodixanol and LOCM groups.

This is contrary to earlier research suggesting iodixanol caused less kidney damage than LOCM. This conclusion led to the current ACC/AHA guidelines recommending iso-osmolar contrast media in NSTE ACS patients with chronic kidney disease undergoing angiography.

In light of the new data, the ACC/AHA guidelines may change, and subsequently drive the adoption of less expensive imaging alternatives that are just as effective as the more costly iodixanol, such as Bracco’s iopamidol or Isovue.

For more information: www.bracco.com

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...